Yes, people do take omeprazole and methotrexate together, but there is a documented major interaction between them that requires careful medical oversight. When used together, omeprazole can reduce the body's ability to clear methotrexate, potentially causing methotrexate and its metabolite hydroxymethotrexate to accumulate to higher and longer-lasting levels in the bloodstream. This accumulation may increase the risk of methotrexate-related toxicities. This article explains what the medical literature shows, how this interaction works, and what questions patients and caregivers should bring to their pharmacist or physician.
The interaction between omeprazole and methotrexate is classified as major in severity. According to the documented source record from FDA labeling data, concomitant use of omeprazole with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, with a possible consequence of methotrexate toxicities.
The mechanism is identified as decreased methotrexate clearance. In other words, the presence of omeprazole reduces the rate at which the body eliminates methotrexate from the bloodstream. This is the controlling source for all pair-specific claims in this article.
This interaction is significant enough to be flagged in drug-information systems and clinical decision-support tools used in hospitals and pharmacies nationwide. The classification of major severity reflects that the potential clinical consequences warrant active medical management rather than routine monitoring alone.
Omeprazole is a proton pump inhibitor (PPI), a class of medications that reduce stomach acid production. It is widely used to treat acid reflux, heartburn, and certain types of ulcers. Omeprazole works by blocking the proton pumps in stomach lining cells that actively secrete acid.
Beyond its effects on stomach acid, omeprazole also influences how the body metabolizes and eliminates certain drugs. This is not a direct action by omeprazole on the stomach—it is a systemic effect that occurs in the liver and kidneys.
Methotrexate is a folate antagonist used in two very different contexts: as a chemotherapy agent in cancer treatment, and in much lower doses as an immunosuppressant for autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain forms of vasculitis. The drug works by interfering with folate metabolism and rapidly dividing cells.
Methotrexate is ultimately eliminated from the body through a combination of kidney filtration and hepatic metabolism. Because methotrexate and its active metabolite hydroxymethotrexate are potent and have a narrow therapeutic window, the rate at which they are removed from the bloodstream directly affects their safety and efficacy.
The documented mechanism is decreased methotrexate clearance. The source record does not specify the detailed biochemical pathway by which omeprazole causes this decrease. However, general pharmacological knowledge indicates that PPIs can inhibit certain renal tubular transporters and may alter hepatic metabolism, both of which are involved in removing methotrexate from the body.
When clearance is reduced, the drug lingers in the bloodstream longer and at higher concentrations. For a drug like methotrexate, which is used precisely because it is potent but must be carefully dosed, this accumulation can shift the balance between benefit and harm toward the side of toxicity.
Methotrexate toxicity can affect multiple organ systems. Common and serious adverse effects include bone marrow suppression (leading to anemia, low platelet counts, and infection risk), hepatotoxicity (liver damage), nephrotoxicity (kidney damage), and gastrointestinal toxicity (mouth sores, nausea, diarrhea). Because methotrexate is often used long-term in autoimmune conditions, cumulative toxicity is a particular concern.
The documented interaction describes a mechanism that would increase methotrexate levels, and thus increase the potential for these toxicity outcomes. This is why the interaction is rated major: the stakes are clinically significant.
Because methotrexate is used in very different dose ranges and contexts—high-dose chemotherapy for cancer versus low-dose immunosuppression for arthritis—the urgency and manner of managing this interaction may differ. However, the documented interaction itself applies regardless of the indication or dose.
Patients taking both drugs should not assume that their doctor is automatically aware of the interaction, especially in settings where prescriptions may be filled at different pharmacies or specialists may not routinely coordinate. Conversely, many clinicians do recognize this interaction and may already be monitoring closely or have a management plan in place. The key is explicit communication.
Caregivers and family members should be aware that accumulation of methotrexate may develop gradually and may not produce immediate symptoms. Some toxicities (such as mild elevations in liver enzymes or subtle bone marrow changes) are detected only through laboratory monitoring.
Consider a patient with rheumatoid arthritis who has been stable on methotrexate 20 mg weekly for two years. Recent onset of acid reflux prompts their physician to prescribe omeprazole. In the weeks that follow, suppose laboratory monitoring (which the patient may or may not have scheduled) were to reveal a rise in liver enzyme markers or a drop in white blood cell count. The documented mechanism—decreased methotrexate clearance—is consistent with this finding. In reality, such a patient would require discussion with their rheumatologist and pharmacist about whether the omeprazole is necessary, whether an alternative acid-reflux medication is safer, or whether methotrexate dosing or monitoring intervals need adjustment. This is a hypothetical scenario intended only to illustrate how the documented interaction might manifest in practice.
A patient undergoing chemotherapy for lymphoma receives high-dose methotrexate as part of their protocol. Concurrent omeprazole use for chemotherapy-related nausea could theoretically allow methotrexate to accumulate despite aggressive supportive care (such as hydration and leucovorin rescue). The higher baseline methotrexate concentrations make any reduction in clearance more consequential. Again, this is hypothetical, but it illustrates why the interaction warrants particular attention in this setting. In practice, oncologists are often highly alert to methotrexate pharmacokinetics and may use alternative antiemetics or adjust monitoring.
If you are taking or considering taking both omeprazole and methotrexate, here are source-grounded questions and considerations to bring up with your healthcare team:
Do not stop, change, or skip either medication on your own based on reading this article. Any modification must be coordinated with your prescriber and pharmacist.
This article provides educational context for a documented drug interaction sourced from FDA labeling and standard medical databases. It is not a substitute for individualized medical advice. If you are taking omeprazole, methotrexate, or both, visit checkdruginteractions.com to review your complete medication list and check for additional interactions. Always confirm any medication decisions—including whether to start, continue, adjust, or stop a drug—with your pharmacist or physician. Your healthcare team has access to your full medical history, current diagnoses, and laboratory results, and is best positioned to weigh the risks and benefits of this combination in your specific situation.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Learn about the documented moderate interaction between empagliflozin and diuretics, how it affects fluid balance, and what monitoring yo...
Amiodarone significantly increases risk of muscle damage from simvastatin. FDA limits simvastatin to 20 mg daily with amiodarone.
FDA documentation shows ritonavir greatly increases sildenafil levels, making this combination contraindicated without strict dose limits.